Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results. -
Early Treatment for Smoldering Multiple Myeloma
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies. -
The Confounding Case of Venetoclax in Multiple Myeloma
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo. -
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Cardiovascular AEs Common With Carfilzomib in Multiple Myeloma
Recommendations Issued for Imaging Use in Multiple Myeloma
Smoldering Myeloma Risk Models Identified High-Risk Patients in the Real World
Pneumococcal Vaccination Induces Antibody Responses in Patients With Multiple Myeloma
Addition of Daratumumab to Frontline Treatment May Improve Outcomes in Transplant-Eligible Patients With Multiple Myeloma
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
